[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
June 7, 2000

New Therapy for Macular Degeneration

Author Affiliations

Not Available

Not Available

JAMA. 2000;283(21):2779. doi:10.1001/jama.283.21.2779-JFD00004-2-1

The FDA has approved verteporfin for injection (Visudyne, QLT Photo Therapeutics, Vancouver, BC, and CIBA Vision, Duluth, Ga) for the treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization (CNV). The treatment is a two-stage process requiring administration of verteporfin for injection followed by light at a wavelength of/689±3nm from a nonthermal diode laser. Light activation of verteporfin in the plasma results in local damage to neovascular endothelium and consequent vessel occlusion.

First Page Preview View Large
First page PDF preview
First page PDF preview